|
Palo Alto, CA, September 19, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and
chief executive officer, will present a company update at the UBS
Global Life Sciences Conference in New York City on September 24,
2003 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time). A live
webcast of the presentation will be accessible at Telik’s
website, www.telik.com. An archive of the webcast will be available
on the Telik website from September 25 through October 1, 2003.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™ (TLK286), in a Phase 3 registration trial in advanced
ovarian cancer and in Phase 2 clinical trials in ovarian, non-small
cell lung and breast cancer. TELINTRA™ (TLK199) is in a Phase
1-2a trial in myelodysplastic syndrome, a form of pre-leukemia.
Telik’s product candidates were discovered using its proprietary
drug discovery technology, TRAP, which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information
is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
